Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings

By Mladsi Deirdre M.   Grogg Amy L.   Irish William D.   Lopez Rebecca B.   Degen Kathleen   Swann Alan   Nimsch Christian T.  

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 1883-1893

Informa Healthcare

Access to resources Recommend Favorite

Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia

By Zhao Zhongyun  

Current Medical Research and Opinion, Vol. 20, Iss. 7, 2004-07 ,pp. : 1039-1048

Informa Healthcare

Access to resources Recommend Favorite

Measures of quality, costs and equity in primary health care: instruments developed to analyse and compare primary health care in 35 countries

By Schäfer Willemijn L.A.  

Quality in Primary Care, Vol. 21, Iss. 2, 2013-05 ,pp. : 67-79

Radcliffe Press

Access to resources Recommend Favorite

Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia

By Ascher-Svanum Haya   Stensland Michael D.   Peng Xiaomei   Faries Douglas E.   Stauffer Virginia L.   Osuntokun Olawale O.   Kane John M.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 115-122

Informa Healthcare

Access to resources Recommend Favorite

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

By Faries Douglas E.   Ascher-Svanum Haya   Nyhuis Allen W.   Kinon Bruce J.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1399-1405

Informa Healthcare

Access to resources Recommend Favorite